[Diffusion of co-tetroxazin into prostatic tissue (author's transl)]

Area of Science:

• Pharmacokinetics and Drug Distribution
• Uro-oncology
• Antimicrobial Chemotherapy

Context:

• Prostate adenoma is a common condition in aging men.
• Understanding drug penetration into prostate tissue is crucial for effective treatment of associated infections.
• Tetroxoprim (TXP) and sulfadiazine (SDZ) are antibiotics with potential applications in treating prostate conditions.

Purpose:

• To quantify and compare the tissue and plasma levels of tetroxoprim (TXP) and sulfadiazine (SDZ) in patients with prostate adenoma.
• To determine the prostate-to-plasma distribution coefficients for TXP and SDZ.

Summary:

• Tissue levels of tetroxoprim (TXP) were 10.75 ± 5.83 µg/g and sulfadiazine (SDZ) were 8.52 ± 3.88 µg/g in prostate adenoma patients.
• Plasma levels were 1.54 ± 0.53 µg/ml for TXP and 17.39 ± 6.11 µg/ml for SDZ.
• The resulting prostate/plasma coefficients were 8.26 for TXP and 0.48 for SDZ, indicating preferential accumulation of TXP in prostate tissue.

Impact:

• These findings suggest that tetroxoprim may achieve significantly higher concentrations within prostate tissue compared to sulfadiazine.
• The differential tissue penetration could influence the choice of antibiotic therapy for prostate infections.
• Further research may explore the clinical efficacy of TXP in treating bacterial prostatitis or other prostate-related conditions.